Defibrotide Sodium

• Defibrotide Sodium is a medication approved for the treatment of severe hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation.
• Its primary action involves protecting endothelial cells and modulating fibrinolysis, rather than direct anticoagulation.
• Common adverse effects include bleeding and hypotension, necessitating careful patient monitoring.
• The drug is administered intravenously and requires strict adherence to dosage and administration guidelines due to its critical use in a vulnerable patient population.

What is Defibrotide Sodium and Its Uses?

Defibrotide Sodium is a complex mixture of single-stranded oligodeoxyribonucleotides derived from porcine intestinal mucosa. It is a crucial therapeutic agent in a very specific and severe medical context. The primary indication for which what is defibrotide sodium used for is the treatment of severe hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT).

Hepatic VOD/SOS is a serious and potentially fatal complication of HSCT, characterized by damage to the small blood vessels of the liver, leading to liver dysfunction and multi-organ failure. This condition can affect a significant percentage of HSCT recipients, and severe forms carry a high mortality rate. Defibrotide Sodium offers a targeted approach to manage this critical complication, improving outcomes for patients who develop severe VOD/SOS.

Defibrotide Sodium: Mechanism of Action

The precise and complete defibrotide sodium mechanism of action is multifaceted and not fully elucidated, but it is understood to exert its therapeutic effects primarily through protective actions on endothelial cells and modulation of fibrinolysis. Unlike traditional anticoagulants, Defibrotide Sodium does not directly inhibit coagulation factors or platelet aggregation.

Instead, it is believed to enhance the activity of endothelial cells, promoting the production and release of prostacyclin (PGI2) and tissue plasminogen activator (t-PA). PGI2 is a potent vasodilator and inhibitor of platelet aggregation, while t-PA facilitates the breakdown of fibrin clots. By restoring the balance between procoagulant and anticoagulant activities at the endothelial surface, Defibrotide Sodium helps to prevent further microvascular damage, reduce thrombosis, and improve blood flow in the hepatic sinusoids, which are critically affected in VOD/SOS.

Side Effects, Warnings, and Drug Information

As with any potent medication, there are important defibrotide sodium side effects and warnings that healthcare providers and patients must be aware of. Given its use in critically ill patients, careful monitoring is essential. The most significant warning is the risk of hemorrhage. Because Defibrotide Sodium affects fibrinolysis, it can increase the risk of bleeding, especially in patients who are already at high risk due to their underlying condition or concomitant medications.

Commonly reported side effects include:

• Hemorrhage (e.g., gastrointestinal, pulmonary, epistaxis)
• Hypotension (low blood pressure)
• Diarrhea
• Nausea and vomiting
• Sepsis
• Hypersensitivity reactions

Regarding general defibrotide sodium drug information, it is administered as an intravenous infusion. Dosage is typically weight-based, and treatment duration is determined by clinical response and resolution of VOD/SOS symptoms. It is contraindicated in patients with known hypersensitivity to the drug or any of its components. Caution is advised when used concomitantly with systemic anticoagulants or thrombolytic agents, and the benefits must be carefully weighed against the increased risk of bleeding. Close monitoring of coagulation parameters and signs of bleeding is crucial throughout treatment.